Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

SLC17A8 (Q8NDX2) - Overview - Molecular Target Synopsis

Protein


SLC17A8, Vesicular glutamate transporter 3
UniProt Q8NDX2

Also Known as VGLU3_HUMAN, SLC17A8, VGLUT3

Mediates the uptake of glutamate into synaptic vesicles at presynaptic nerve terminals of excitatory neural cells. May also mediate the transport of inorganic phosphate.

Isoforms / Transcripts (Protein Coding)


Protein Length Ensembl Gene Ensembl Transcript Ensembl Protein Uniprot Isoform
589ENSG00000179520ENST00000323346ENSP00000316909Q8NDX2-1
539ENSG00000179520ENST00000392989ENSP00000376715Q8NDX2-2

Sub-cellular localization


UniProt: SLC17A8 is active in the following subcellular-locations: cell junction, cytoplasmic vesicle, membrane, secretory vesicle, synapse, synaptic vesicle membrane, synaptosome.
GO terms: SLC17A8 is active in the following subcellular-locations: apical dendrite, axon terminus, basal dendrite, cell junction, excitatory synapse, glial limiting end-foot, integral component of membrane, integral component of synaptic vesicle membrane, multivesicular body, pericellular basket, perikaryon, synaptic vesicle membrane.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project SLC17A8 has gain in 1 cell-lines, loss in 0 cell-lines and no signal in 1004 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are:

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: SK-N-DZ, Hs 746T, NCI-H209

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: SK-N-SH, NHLF, HSMM

(see details)


Screening and Chemistry


SLC17A8 has been screened with compounds ( bioactivities). (see details)